Advancements in Glomerulonephritis Treatment: The Impact of Recent Clinical Trials

IgA NEPHROPATHYIgAN is a progressive, immune complexmediated disease, and the most common primary glomerulonephritis, representing the leading cause of chronic kidney and end-stage renal disease.The mechanism of IgAN involves the formation and deposition of circulating IgA-immune complexes in the glomeruli, triggering inflammation scarring, nephron loss, and ultimately kidney failure.Johnathon Barratt, University of Leicester, UK, commenced the session by delivering a talk on the transformative progress of clinical trials for IgAN.For two-thirds of Barratt's career, the clinical trial landscape for IgAN resembled a desolate desert, with patients relying on renin-angiotensinaldosterone system inhibition (RAAS-i) and lifestyle modifications, inevitably destined for dialysis.However, over the past decade, this stagnation has given way to an explosion in new clinical trial activities.Barratt attributes this shift to several critical factors, including regulatory changes, enhanced understanding of disease pathogenesis, and evolving clinical guidelines.